A phase I study of ultra low dose interleukin-2 and stem cell factor in patients with HIV infection or HIV and cancer

Clinical Cancer Research

Volumn 12, Issue 13, 2006, Pages 3993-3996

  Shah, Manisha H ^a,b   Freud, Aharon G ^a   Benson Jr , Don M ^a   Ferkitich, Amy K ^a   Dezube, Bruce J ^c,d   Bernstein, Zale P ^c,e   Caligiuri, Michael A ^a,b,c,f  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c Beth Israel Deaconess Medical Center ^*

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e ROSWELL PARK CANCER INSTITUTE   (United States)

^f Cancer and Leukemia Group B   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; BILIRUBIN; CERTRIZINE; CREATININE; CYTOKINE; HISTAMINE H1 RECEPTOR ANTAGONIST; LACTATE DEHYDROGENASE; RANITIDINE; RECOMBINANT INTERLEUKIN 2; RECOMBINANT STEM CELL FACTOR; SALBUTAMOL; UNCLASSIFIED DRUG;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ALLERGY; AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER; CANCER PATIENT; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEPRESSION; DIARRHEA; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EDEMA; EOSINOPHILIA; ERYTHEMA; FATIGUE; FEVER; FLUSHING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; IN VIVO STUDY; INJECTION PAIN; LACTATE DEHYDROGENASE BLOOD LEVEL; LOW DRUG DOSE; MAXIMUM TOLERATED DOSE; MYALGIA; NATURAL KILLER CELL; NAUSEA; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; REGULATORY T LYMPHOCYTE; RESTLESSNESS; SIDE EFFECT; SKIN TINGLING; SORE THROAT; SWEATING; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; UPPER RESPIRATORY TRACT INFECTION; UREA NITROGEN BLOOD LEVEL; URTICARIA; WEIGHT GAIN;

ADULT; ANTIGENS, CD56; COHORT STUDIES; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG TOXICITY; HIV; HIV INFECTIONS; HUMANS; INFUSIONS, INTRAVENOUS; INTERLEUKIN-2; KILLER CELLS, NATURAL; LYMPHOMA, NON-HODGKIN; MAXIMUM TOLERATED DOSE; MIDDLE AGED; REMISSION INDUCTION; STEM CELL FACTOR; T-LYMPHOCYTES, REGULATORY; TREATMENT OUTCOME;

EID: 33746083616     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0268     Document Type: Article

References (22)

1. Robertson MJ, Ritz J. Biology and clinical relevance of human natural killer cells. Blood 1990;76:2421-38.
2. Bancroft GJ. The role of natural killer cells in innate resistance to infection. Curr Opin Immunol 1993;5:503-10.
3. Matos ME, Schnier GS, Beecher MS, Ashman LK, William DE, Caligiuri MA. Expression of a functional c-kit receptor on a subset of natural killer cells. J Exp Med 1993;178:1079-84.
4. Fehniger TA, Carson WA, Mrozek E, Caligiuri MA. Stem cell factor enhances interleukin-2-mediated expansion of murine natural killer cells in vivo. Blood 1997;90:3647-53.
5. Yu H, Fehniger TA, Fuchshuber P, et al. Flt3 ligand promotes the generation of a distinct CD34(+) human natural killer cell progenitor that responds to interleukin-15. Blood 1998;92:3647-57.
6. + hematopoietic progenitor cells. Blood 1996;87:2632-40.
7. Carson WE, Haldar S, Baiocchi RA, Croce CM, Caligiuri MA. The c-kit ligand suppresses apoptosis of human natural killer cells through upregulation of bcl-2. Proc Natl Acad Sci U S A 1994;91:7553-7.
8. Bernstein ZP, Porter MM, Gould M, et al. Prolonged administration of low-dose interleukin-2 in human immunodeficiency virus-associated malignancy results in selective expansion of innate immune effectors without significant clinical toxicity. Blood 1995;86:3287-94.
9. Katri VP, Fehniger TA, Baiocchi RA, et al. Ultra low dose interleukin-2 therapy promotes a type 1 cytokine profile in vivo in patients with AIDS and AIDS-associated malignancies. J Clin Invest 1998;101:1373-8.
10. Freud AG, Becknell B, Roychowdhury S, et al. A human CD34(+) subset resides in lymph nodes and differentiates into CD56bright natural killer cells. Immunity 2005;22:295-304.
11. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor foxP3. Science 2003;299:1057-61.
12. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995;155:1151-64.
13. + T helper cells and hindered by naturally occurring T regulatory cells. J Immunol 2005;174:2591-601.
14. Kovacs JA, Baseler M, Dewar RJ, et al. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study. N Engl J Med 1995;332:567-75.
15. Turk MJ, Guevara-Patino JA, Rizzuto GA, Engelhorn ME, Sakaguchi S, Hougton AN. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Ex Med 2004;200:771-82.
16. Wei WZ, Morris GP, Kong YC. Anti-tumor immunity and autoimmunity: a balancing act of regulatory T cells. Cancer Immunol Immunother 2004;53:73-8.
17. + regulatory T cells is necessary, but not sufficient, for induction of organ-specific autoimmune disease. J Immunol 2002;168:5979-83.
18. Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC. Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 1997;89:1138-47.
19. CTEP. NCI: Common Toxicity Criteria manual, version 2.0. Bethesda (MD): National Cancer Institute; 1999. p. 1-35.
20. + T cells expressing foxP3 in IL-2 treated HIV-infected patients. J Clin Invest 2005;115:1839-47.
21. + regulatory T cells. Nat Med 2005;11:1238-43.
22. + HIV-specific T cell immune responses in vitro and are associated with favorable clinical makers of disease status. J Exp Med 2004;200:311-43.